Small molecule orphan drugs: Balancing financial incentives and complex challenges

Small molecule orphan drugs: Balancing financial incentives and complex challenges For companies pursuing an orphan drug, successfully traversing the path to regulatory submission requires striking the right balance of speed-to-clinic and cost. While there is no one-size-fits-all approach, shared characteristics of successful development projects include:
  • Early and frequent engagement with regulatory authorities
  • Alignment of CMC and clinical activities
  • Transparent communication among internal and external stakeholders
  • An integrated vendor strategy
In this whitepaper, our experts help guide you through the complex challenges of getting your small molecule orphan drug to market faster.

Resource Library

Related Sites

Previous
Next

Additional Resources

Previous
Next
Patheon on LinkedIn
Patheon on Twitter
Patheon YouTube Channel
© 2021 Thermo Fisher Scientific Inc. All rights reserved. Cookie UsePrivacyTerms of UseModern Slavery Statement
Patheon on LinkedIn Patheon on Twitter Patheon YouTube Channel
Cookie UsePrivacyTerms of UseModern Slavery Statement
© 2021 Thermo Fisher Scientific Inc. All rights reserved.